Gabelli Funds LLC cut its position in Amedisys, Inc. (NASDAQ:AMED – Free Report) by 0.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 223,402 shares of the health services provider’s stock after selling 723 shares during the quarter. Gabelli Funds LLC owned about 0.68% of Amedisys worth $20,589,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in the company. Calamos Advisors LLC bought a new position in shares of Amedisys during the fourth quarter worth approximately $23,015,000. Wolverine Asset Management LLC raised its holdings in Amedisys by 13.9% in the 4th quarter. Wolverine Asset Management LLC now owns 35,181 shares of the health services provider’s stock valued at $3,344,000 after acquiring an additional 4,299 shares in the last quarter. Allianz Asset Management GmbH raised its holdings in Amedisys by 146.0% in the 4th quarter. Allianz Asset Management GmbH now owns 39,855 shares of the health services provider’s stock valued at $3,789,000 after acquiring an additional 23,655 shares in the last quarter. Water Island Capital LLC lifted its position in shares of Amedisys by 185.0% during the 4th quarter. Water Island Capital LLC now owns 710,697 shares of the health services provider’s stock valued at $67,559,000 after acquiring an additional 461,368 shares during the period. Finally, Nomura Holdings Inc. increased its position in shares of Amedisys by 604.2% in the fourth quarter. Nomura Holdings Inc. now owns 49,297 shares of the health services provider’s stock worth $4,686,000 after purchasing an additional 42,297 shares during the period. 94.36% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on AMED. StockNews.com upgraded shares of Amedisys from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $101.00 target price on shares of Amedisys in a report on Thursday. Finally, William Blair cut Amedisys from an “outperform” rating to a “market perform” rating in a report on Monday, July 1st. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $100.67.
Amedisys Trading Up 0.5 %
AMED traded up $0.50 during midday trading on Friday, hitting $98.25. 1,410,227 shares of the company were exchanged, compared to its average volume of 494,022. The firm’s 50 day moving average price is $94.89 and its 200-day moving average price is $93.82. Amedisys, Inc. has a 1-year low of $89.55 and a 1-year high of $98.95. The firm has a market capitalization of $3.21 billion, a P/E ratio of -153.51, a P/E/G ratio of 2.37 and a beta of 0.79. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.31.
Amedisys (NASDAQ:AMED – Get Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The health services provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Amedisys had a net margin of 4.02% and a return on equity of 12.56%. The firm had revenue of $571.41 million for the quarter, compared to the consensus estimate of $565.38 million. During the same quarter in the previous year, the company earned $1.00 EPS. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. As a group, equities analysts forecast that Amedisys, Inc. will post 4.62 EPS for the current fiscal year.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Articles
- Five stocks we like better than Amedisys
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Why Call Options Volume for These 2 Stocks Spiked Together
- Business Services Stocks Investing
- MarketBeat Week in Review – 7/22 – 7/26
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc. (NASDAQ:AMED – Free Report).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.